Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.00 (0.00%)
Bid:
2.60
Ask:
2.80
Spread: 0.20 (7.692%)
Market Cap: £19.52m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

IP Licensing

24 Sep 2010 07:00

RNS Number : 2356T
Amphion Innovations PLC
24 September 2010
 

Amphion Innovations plc

IP Licensing

 

London and New York, 24 September 2010 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that its wholly owned subsidiary, DataTern, Inc., has settled certain pending patent infringement litigation over its U.S. Patents 6,101,502 and 5,937,402, generating total revenues of $500,000.

 

DataTern has signed 22 licenses of these patents since June 2008, generating total revenues of approximately $14 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, airline, e-commerce, and software industries.

 

DataTern, Inc., was originally established in order to commercialise selected intellectual property opportunities in partnership with Amphion's Partner Companies. As part of the licensing programme described above, DataTern offers to license all parties in all industries under these patents.

 

For further information please contact:

Amphion Innovations plc Charlie Morgan +44 779 953 6043

 

Cardew Group Tim Robertson/ Jamie Milton +44 20 7930 0777

 

Charles Stanley (Nominated Adviser) Mark Taylor +44 20 7149 6000

 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number that grows rapidly each year.

 

On the web: www.amphionplc.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUOABRRKAKUAR
Date   Source Headline
30th Apr 20082:58 pmRNSTotal Voting Rights
8th Apr 20087:00 amRNSPartner Company Fundraising
7th Apr 20083:46 pmRNSFundraising
26th Mar 200812:36 pmRNSDirector/PDMR Shareholding
13th Mar 20087:12 amRNSFinal Results
3rd Mar 20087:01 amRNSPrivateMarkets Fundraising
27th Feb 20088:00 amRNSNotice of Preliminary Results
31st Jan 20084:51 pmRNSTotal Voting Rights
17th Jan 20087:01 amRNSTrading Statement
7th Jan 20087:00 amRNSDirectors Dealings
30th Nov 20074:53 pmRNSTotal Voting Rights
12th Nov 20077:01 amRNSIssue of Equity
5th Nov 20071:59 pmRNSResult of EGM
5th Nov 20071:39 pmRNSResult of EGM
31st Oct 20075:49 pmRNSTotal Voting Rights-Amendment
31st Oct 20072:18 pmRNSTotal Voting Rights
29th Oct 20077:00 amRNSWellGen Series C Financing
12th Oct 20077:30 amRNSIssue of Equity
12th Sep 20077:01 amRNSInterim Results
28th Aug 200710:25 amRNSNotice of Results
22nd Aug 20077:01 amRNSChange of Adviser
16th Aug 20079:31 amRNSRe: AIM Rule 26
14th Aug 20077:00 amRNSFundraising
30th Jul 20077:01 amRNSRe: Series C Financing
12th Jul 20079:19 amRNSPatent Awarded
2nd Jul 20077:01 amRNSPlacing
7th Jun 20077:01 amRNSAGM Statement
21st May 20071:52 pmRNSRe: Symposium
21st May 20071:00 pmBUSApplied Genomics Paves the Way for Improved Prevention, Diagnosis, and Treatment of Disease
14th May 20074:25 pmBUSAmphion Innovations plc (LSE: ''AMP'') Announces First Annual Science & Business Symposium ''Building Market Value from the World of Genetics''
30th Apr 200711:02 amRNSDirector Shareholdings
11th Apr 200711:31 amRNSResearch Update
5th Apr 20071:00 pmBUSAmphion Innovations Partner Company Motif Biosciences Closes $1m Financing
5th Apr 20079:24 amRNSDirector/PDMR Shareholding
5th Apr 20077:01 amRNSRe: Series C Financing
23rd Mar 20072:42 pmBUSPort of Barbados Selects AXCESS to Provide Security Systems for the Cricket World Cup 2007
23rd Mar 20077:01 amRNSRe: Cricket World Cup
15th Mar 20077:01 amRNSFinal Results
26th Feb 20074:44 pmRNSNotice of Results
9th Feb 20077:00 amRNSRe: Financing
16th Jan 20073:25 pmBUSAmphion Innovations, plc Announces Creation of a Gulf-based Joint Venture
16th Jan 20073:19 pmBUSAmphion Innovations, plc Offers Trading Update
16th Jan 20077:01 amRNSJoint Venture
16th Jan 20077:00 amRNSTrading Update
8th Jan 20074:28 pmBUSAmphion Innovations plc Announces Fundraising
8th Jan 20071:08 pmRNSFundraising - Replacement
8th Jan 20077:00 amRNSFundraising
27th Nov 20063:04 pmBUSAmphion Innovations plc Acquires 35% Stake in Manchester Molecular Diagnostic Spin-out Company
27th Nov 20067:00 amRNSAcquires Stake in Company
13th Nov 20062:58 pmBUSAmphion Innovations plc Partner Company Supertron Acquires Spin Systems

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.